Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) α in obese mice

Medical Science Monitor

Volumn 10, Issue 10, 2004, Pages

  Ide, Tomohiro ^a   Tsunoda, Masaki ^a   Mochizuki, Toshiro ^a   Murakami, Koji ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Insulin resistance; Insulin signaling; ob ob mice; Phosphatidylinositol 3 kinase; PPAR

Indexed keywords

ACYL COENZYME A; FATTY ACID; GLUCOSE; INSULIN; INSULIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PIRINIXIC ACID; RECEPTOR SUBTYPE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT; CONTROLLED STUDY; FATTY ACID OXIDATION; GENETIC REGULATION; GROWTH INHIBITION; INSULIN RESISTANCE; LIPID STORAGE; MALE; MOUSE; MUSCLE TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PORTAL VEIN; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; SKELETAL MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BIOLOGICAL MARKERS; GENE EXPRESSION REGULATION; INSULIN; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MUSCLES; OBESITY; PHOSPHOPROTEINS; PHOSPHOTYROSINE; PPAR ALPHA; PYRIMIDINES; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 7044274089     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Kerouz NJ, Horsch D, Pons S, Kahn CR: Differential regulation of insulin receptor substrates-1 and-2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J Clin Invest, 1997; 100: 3164-72
2. Anai M, Funaki M, Ogihara T et al: Altered expression levels and impaired steps in the pathway to phosphatidylinositol 3-kinase activation via insulin receptor substrates 1 and 2 in Zucker fatty rats. Diabetes, 1998; 47: 13-23
3. Cusi K, Maezono K, Osman A et al: Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest, 2000; 105: 311-20
4. Kim YB, Nikoulina SE, Ciaraldi TP et al: Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest, 1999; 104: 733-41
5. Griffin ME, Marcucci MJ, Cline GW et al: Free fatty acid-induced insulin resistance is associated with activation of protein kinase C q and alterations in the insulin signaling cascade. Diabetes, 1999; 48: 1270-74
6. Dresner A, Laurent D, Marcucci M et al: Effects of free fatty acids on glucose transport and IRS-I-associated phosphatidylinositol 3-kinase activity. J Clin Invest, 1999; 103: 253-59
7. Boden G, Chen X, Ruiz J et al: Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest, 1994; 93: 2438-46
8. Pan DA, Lillioja S, Kriketos AD et al: Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes, 1997; 46: 983-88
9. Braissant O, Foufelle F, Scotto C et al: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPARα, -β, and -γ in the adult rat. Endocrinology, 1996; 137: 354-66
10. Schoonjans K, Staels B, Auwerx J: The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta, 1996; 1302: 93-109
11. Murakami K, Tobe K, Ide T et al: A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ. effect of PPAR-α activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes, 1998; 47: 1841-47
12. Ide T, Nakazawa T, Mochizuki T, Murakami K: Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats. Metabolism, 2000; 49: 521-25
13. Brown PJ, Winegar DA, Plunket K et al: A Ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARα agonist with potent lipid-lowering activity. The PPARs: from orphan receptors to drug discovery. J Med Chem, 1999; 42: 3785-88
14. Lee HJ, Choi SS, Park MK et al: Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETEF rats. Biochem Biophys Res Commun, 2002; 296: 293-99
15. Koh EH, Kim MS, Park JY et al: Peroxisome proliferator-activated receptor-α activation prevents diabetes in OLETEF rats: comparision with PPAR-γ activation. Diabetes, 2003; 52: 2331-37
16. Kobayashi M, Shigeta Y, Hirata Y et al: Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. Diabetes Care, 1988; 11: 495-99
17. Guerre-Millo M, Gervois P, Raspe E et al: Peroxisome proliferator- activated receptor a activators improve insulin sensitivity and reduce adiposity. J Biol Chem, 2000; 275: 16638-12
18. Ye JM, Doyle PI, Iglesias MA et al: Peroxisome proliferator-activated receptor (PPAR)-a activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-γ activation. Diabetes, 2001; 50: 411-17
19. Wang PR, Guo Q, Ippolito M et al: High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor a selective agonists. Eur J Pharmacol, 2001; 427: 285-93
20. Kim H, Haluzik M, Asghar Z et al: Peroxisome proliferator-activated receptor a agonist treatment in a transgenic model of type 2 diabetes reserves the lipotoxic state and improves glucose homeostasis. Diabetes, 2003; 52: 1770-78
21. Chou CJ, Haluzik M, Gregory C et al: WY14,643, a peroxisome proliferator-activated receptor a (PPARα) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-I mice. J Biol Chem, 2002; 277: 24484-89
22. Murakami K, Ide T, Nakazawa T et al: Fatty-acyl-CoA thioesters inhibit recruitment of steroid receptor co-activator 1 to a and g isoforms of peroxisome-proliferator-activated receptors by competing with agonists. Biochem J, 2001; 353: 231-38
23. Hofmann C, Lorenz K, Braithwaite SS et al: Altered gene expression for tumor necrosis factor-a and its receptors during drug and dietary modulation of insulin resistance. Endocrinology, 1994; 134: 264-70
24. Minnich A, Tian N, Byan L, Bilder G: A potent PPARα agonist stimulates mitochondrial fatty acid β-oxidation in liver and skeletal muscle. Am J Physiol, 2001; 280: E270-79
25. Muoio DM, Way JM, Tanner CJ et al: Peroxisome-proliferator-activated receptor-a regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes, 2002; 51: 901-9
26. Ruderman N, Saha AK, Vavvas D, Witters LA: Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol, 1999; 276: E1-E18
27. Furuhashi M, Ura N, Murakami H et al: Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and b-oxidation in skeletal muscle. J Endocrinol, 2002; 174: 321-29
28. Bruce JS, Salter AM: Metabolic fate of oleic acid, palmiric acid and stearic acid in cultured hamster hepatocytes. Biochem J, 1996; 316: 847-52
29. DeLany JP, Windhauser MM, Champagne CM, Bray GA: Differential oxidation of individual dietary fatty acids in humans. Am J Clin Nutr, 2000; 72: 905-11
30. Saad MJ, Araki E, Miralpeix M et al: Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. J Clin Invest, 1992; 90: 1839-49
31. Hotanusligil GS, Budavari A, Murray D, Spiegelman BM: Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: Central role of tumor necrosis factor-a. J Clin Invest, 1994; 94: 1543-49
32. Youngren JE, Paik J, Barnard RJ: Impaired insulin-receptor autophosphorylation is an early defect in fat-fed, insulin-resistant rats. J Appl Physiol, 2001; 91: 2240-47
33. Storz P, Doppler H, Wernig A et al: Cross-talk mechanisms in the development of insulin resistance of skeletal muscle cells: palmitate rather than tumor necrosis factor inhibits insulin-dependent protein kinase B (PKB)/Akt stimulation and glucose uptake. Eur J Biochem, 1999; 266: 17-25
34. Gumbiner B, Mucha JF, Lindstrom JE et al: Differential effects of acute hypertriglycerdemia on insulin action and insulin receptor autophosphorylation. Am J Physiol, 1996; 270: E424-E429
35. Kim JK, Kim YJ, Fillmore JJ et al: Prevention of fat-induced insulin resistance by salicylate. J Clin Invest, 2001; 108: 437-46
36. Yuan M, Konstantopoulos N, Lee J et al: Reversal of obesity- and diet-induced insulin resistance with salicylates of targeted disruption of IKKb. Science, 2001; 293: 1673-77
37. Kido Y, Burks DJ, Withers D et al: Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest, 2000; 105: 199-205
38. Yamauchi T, Tobe K, Tamemoto H et al: Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice. Mol Cell Biol, 1996; 16: 3074-84
39. Rother KI, Imai Y, Caruso M et al: Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes. J Biol Chem, 1998; 273: 17491-97
40. Withers DJ, Burks DJ, Towery HH et al: IRS-2 coordinates IGF-1 receptor-mediated b-cell development and peripheral insulin signalling. Nat Genet, 1999; 23: 32-40
41. Shimomura I, Matsuda M, Hammer RE et al: Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell, 2000; 6: 77-86